Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven, global lifesciences company has announced that four abstracts on Saroglitazar Mg will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 – 8, 2022).

Four abstracts are: Saroglitazar Improves Atherogenic Risk in Patients with Nonalcoholic Fatty Liver Disease: Pooled Analysis from Randomized Controlled Trials [Publication Number: 2598]; Saroglitazar versus Vitamin E in patients with biopsy proven NASH: a randomised controlled trial [Publication Number: 2390]; Safety and efficacy of saroglitazar in potential voluntary live liver donors with mild to moderate hepatic steatosis.

Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis (PBC) and Phase 2b in patients with Non- alcoholic Steatohepatitis (NASH).

The USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC. The European Medicines Agency (EMA) has designated "Saroglitazar magnesium" with Orphan status for Treatment of Primary Biliary Cholangitis.

NASH is a chronic liver disease characterised by fat accumulation and inflammation in the liver, which can progress to liver cirrhosis, need for liver transplant or death. There are currently no drugs approved in the USA for treatment of NASH – a global unmet medical need.

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.